Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Arizona is the first state to enact a law to allow drug companies to communicate off-label uses of their products. A conservative think tank is hoping other states will follow suit.
The Free Speech in Medicine Act ( H.B. 2382), signed March 21 by Arizona Gov. Doug Ducey (R), allows drug companies to communicate with doctors and other health-care providers about safe and effective off-label uses for approved medical products. But it doesn’t permit manufacturers to advertise off-label uses directly to the public.
The legislation was drafted by the Goldwater Institute, a Phoenix-based think tank that advocates for limited government. It’s hoping that other states also enact the legislation in order to either push the Food and Drug Administration to allow off-label communication or force a Supreme Court case on the issue.
Doctors can prescribe drugs for off-label uses, meaning uses that aren’t approved by the FDA. However, drugmakers can’t promote or provide information about off-label uses.
The purpose of the legislation is “to protect free speech rights,” Christina Sandefur, executive vice president of the Goldwater Institute and the person who drafted the legislation, told Bloomberg BNA March 31.
While doctors are allowed to prescribe treatments off-label, pharmaceutical companies aren’t allowed to share information about those treatments, she said. “This is a free speech violation.”
Sandefur said there have been a series of court cases where drug companies have sued the FDA for not allowing them to share off-label information. The agency then settles with the company, which keeps any precedent from being set on this, she said. No case has ever gotten to the U.S. Supreme Court.
“While federal law does preempt state law, a federal law that’s unconstitutional doesn’t,” Sandefur said.
Sandefur said one of two things may happen in Arizona. Either the FDA may decide not to step in or prosecute anyone, or the FDA will step in. If the FDA takes action, this would establish a legal challenge that can’t be settled and would force the issue up to the Supreme Court, she said.
“Hopefully lawmakers in other states will follow suit,” Sandefur said. The Arizona law passed unanimously and this shows that “people recognize how important this is for patients.”
The Goldwater Institute also has pushed for states to enact “right to try” laws, which have now been adopted in 33 states. These laws allow terminally ill patients to get access to treatments that are being studied in clinical trials but haven’t yet been approved by the FDA.
Little will change for off-label communications until the FDA modifies its policies, according to sources contacted by Bloomberg BNA.
“The state law can effectively remove state penalties, and that’s what it’s done. But it doesn’t touch the federal requirements. They remain in place and the law of the land,” Bradley Merrill Thompson, a Washington-based health-care attorney with Epstein Becker & Green PC, told Bloomberg BNA in a March 29 email. “This really seems more of a symbolic act, than anything with practical effect.”
Deborah M. Shelton, a partner in the FDA Practice Group of McCarter & English in Washington, also told Bloomberg BNA in an email, “while this state-law approach helps to continue to shine a spotlight on the overarching need for greater flexibility in manufacturer’s medical product communications with health-care providers, it is not any sort of game-changer from a substantive standpoint.”
“This sort of state approach may help to constrain those going forward in a specific state with this type of law, but it is FDA that has the significant authority under federal law to regulate most manufacturer communications,” Shelton said. “Thus, it remains of critical importance that FDA modernize its regulatory framework governing product communications, separate and apart from whatever limited relief state law may provide. Without FDA acting as the change agent, whether through a federal legislative mandate or by its own regulations, the current environment of significant uncertainty and extensive litigation will continue.”
Thompson and Shelton are both Bloomberg BNA advisory board members.
A Pharmaceutical Research and Manufacturers of America (PhRMA) spokeswoman told Bloomberg BNA in a March 29 email that PhRMA didn’t take a position on Arizona’s legislation. “Our companies follow federal FDA regulations and laws on off-label promotion of medicines,” she said.
Bloomberg Intelligence Analyst Brian Rye told Bloomberg BNA in an email “the FDA does dictate off-label promotion, but it’s worth noting that they’re re-examining their policies in the wake of some legal decisions suggesting that a prohibition on truthful discussions may have First Amendment implications.” For example, the FDA held a public meeting in November 2016 to seek stakeholder input on off-label promotion.
Rye said President Donald Trump’s nominee to head the FDA, Scott Gottlieb, “is likely to support relaxing the agency’s existing restrictions on communications between drugmakers and payers, both pre- and post-approval.”
John Kamp, director of the Coalition for Healthcare Communication, told Bloomberg BNA in a March 30 email, “the Goldwater Institute and Arizona clearly have the policy right. Truthful off-label information from drug sponsors helps doctors and patients know what is needed to make appropriate treatment decisions.”
“But, according to the law of preemption, these are FDA, not state, policy decisions,” Kamp said.
Kamp said he’s optimistic that Gottlieb “will create rules that make such information sharing the law of the land.” The Coalition for Healthcare Communication, whose members include media, health-care and other organizations, promotes the free exchange of scientific and medical information.
The FDA declined to comment on the Arizona law.
The Arizona law says drug manufacturers can engage in “truthful promotion of an off-label use of a drug, biological product or device.” But it doesn’t say medical device companies also can engage in off-label promotion.
“This is a very odd law,” Epstein Becker & Green’s Thompson told Bloomberg BNA. “For some reason, it only empowers pharmaceutical companies to engage in this off label promotion of drugs or medical devices. It does not allow a medical device manufacturer to do likewise.”
Thompson said, “To me, that’s a constitutional flaw in the Arizona law because there has to be a rational basis to distinguish among speakers when it comes to First Amendment rights, and there would not seem to be a rational basis to distinguish between pharmaceutical and medical device speakers.”
To contact the reporter on this story: Bronwyn Mixter in Washington at email@example.com
To contact the editor responsible for this story: Brian Broderick at firstname.lastname@example.org
The legislation is at https://apps.azleg.gov/BillStatus/GetDocumentPdf/451964.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)